➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Johnson and Johnson
Moodys
Baxter
Harvard Business School

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Urelumab

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Urelumab?

Urelumab is an investigational drug.

There have been 7 clinical trials for Urelumab. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2015.

The most common disease conditions in clinical trials are Lymphoma, Non-Hodgkin, Neoplasms, and Lymphoma, B-Cell. The leading clinical trial sponsors are Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, and M.D. Anderson Cancer Center.

There are seventeen US patents protecting this investigational drug and two hundred and one international patents.

Recent Clinical Trials for Urelumab
TitleSponsorPhase
Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid TumorsClinica Universidad de Navarra, Universidad de NavarraPhase 1/Phase 2
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for CancerBristol-Myers SquibbPhase 1
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for CancerUniversity of ChicagoPhase 1

See all Urelumab clinical trials

Clinical Trial Summary for Urelumab

Top disease conditions for Urelumab
Top clinical trial sponsors for Urelumab

See all Urelumab clinical trials

US Patents for Urelumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Urelumab   Start Trial Immunoregulatory agents Flexus Biosciences, Inc. (Princeton, NJ)   Start Trial
Urelumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Urelumab   Start Trial Constructs having a SIRP-.alpha. domain or variant thereof ALX ONCOLOGY INC. (Burlingame, CA)   Start Trial
Urelumab   Start Trial Methods and compositions for treating conditions associated with an abnormal inflammatory responses First Wave Bio, Inc. (Ann Arbor, MI)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Urelumab

Drugname Country Document Number Estimated Expiration Related US Patent
Urelumab Argentina 102536 2034-11-05   Start Trial
Urelumab Australia 2015342940 2034-11-05   Start Trial
Urelumab Brazil 112017008568 2034-11-05   Start Trial
Urelumab Canada 2964290 2034-11-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Johnson and Johnson
Moodys
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.